Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma

Authors: Julia Freimuth, Nikolaus Gassler, Nives Moro, Rolf W. Günther, Christian Trautwein, Christian Liedtke, Gabriele A. Krombach

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The molecular mechanisms underlying hepatocarcinogenesis are still poorly understood. Genetically modified mice are powerful tools to further investigate the mechanisms of HCC development. However, this approach is limited due to the lack of non-invasive detection methods in small rodents. The aim of this study was to establish a protocol for the non-invasive analysis of hepatocarcinogenesis in transgenic mice using a clinical 1.5 Tesla Magnetic Resonance Imaging scanner.

Results

As a model system we used hepatocyte-specific c-myc transgenic mice developing hepatocellular carcinoma at the age of 12-15 months. The scans of the murine livers included axial T2-weighted turbo-spin echo (TSE) images, axial T1-weighted and contrast enhanced T1-weighted gradient echo (fast field echo, FFE) and sagittal true Fast Imaging with Steady state Precession (true-FISP) images. Application of contrast agent was performed via tail vein-catheter and confirmed by evaluation of the altered longitudinal relaxation T1 time before and after application. Through technical adaptation and optimization we could detect murine liver lesions with a minimum diameter of approximately 2 mm and provided histopathological evidence that these MR findings correspond to hepatocellular carcinoma. Tumor growth was repeatedly measured using sequential MRI with intervals of 5 weeks and subsequent volumetric analysis facilitating direct comparison of tumor progression between individual animals. We finally demonstrated that our protocol is also applicable in the widely- used chemical model of N-nitrosodiethylamine-induced hepatocarcinogenesis.

Conclusion

Our protocol allows the non-invasive, early detection of HCC and the subsequent continuous monitoring of liver tumorgenesis in transgenic mice thereby facilitating future investigations of transgenic tumor mouse models of the liver.
Appendix
Available only for authorised users
Literature
1.
go back to reference Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS: Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene. 2000, 19: 5054-5062. 10.1038/sj.onc.1203885CrossRefPubMed Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS: Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene. 2000, 19: 5054-5062. 10.1038/sj.onc.1203885CrossRefPubMed
2.
go back to reference Santoni-Rugiu E, Jensen MR, Thorgeirsson SS: Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 1998, 58: 123-134.PubMed Santoni-Rugiu E, Jensen MR, Thorgeirsson SS: Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 1998, 58: 123-134.PubMed
3.
go back to reference Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004, 36: 1306-1311. 10.1038/ng1481CrossRefPubMed Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004, 36: 1306-1311. 10.1038/ng1481CrossRefPubMed
4.
go back to reference Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, Trautwein C: Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology. 2005, 129: 1602-1615. 10.1053/j.gastro.2005.08.007CrossRefPubMed Liedtke C, Zschemisch NH, Cohrs A, Roskams T, Borlak J, Manns MP, Trautwein C: Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology. 2005, 129: 1602-1615. 10.1053/j.gastro.2005.08.007CrossRefPubMed
5.
go back to reference Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857CrossRefPubMed
6.
go back to reference Worns MA, Weinmann A, Schuchmann M, Galle PR: Systemic therapies in hepatocellular carcinoma. Dig Dis. 2009, 27: 175-188. 10.1159/000218351CrossRefPubMed Worns MA, Weinmann A, Schuchmann M, Galle PR: Systemic therapies in hepatocellular carcinoma. Dig Dis. 2009, 27: 175-188. 10.1159/000218351CrossRefPubMed
7.
go back to reference Calvisi DF, Thorgeirsson SS: Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol. 2005, 33: 181-184. 10.1080/01926230590522095CrossRefPubMed Calvisi DF, Thorgeirsson SS: Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol. 2005, 33: 181-184. 10.1080/01926230590522095CrossRefPubMed
8.
go back to reference Sell S: Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003, 63: 7553-7562.PubMed Sell S: Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003, 63: 7553-7562.PubMed
9.
go back to reference Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, Grompe M: Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008, 14: 59-67. 10.1016/j.ccr.2008.05.004PubMedCentralCrossRefPubMed Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, Grompe M: Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008, 14: 59-67. 10.1016/j.ccr.2008.05.004PubMedCentralCrossRefPubMed
10.
go back to reference Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL: Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007, 132: 1465-1475. 10.1053/j.gastro.2007.01.045CrossRefPubMed Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL: Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology. 2007, 132: 1465-1475. 10.1053/j.gastro.2007.01.045CrossRefPubMed
11.
go back to reference Pani G, Fusco S, Colavitti R, Borrello S, Maggiano N, Cravero AA, Farre SM, Galeotti T, Koch OR: Abrogation of hepatocyte apoptosis and early appearance of liver dysplasia in ethanol-fed p53-deficient mice. Biochem Biophys Res Commun. 2004, 325: 97-100. 10.1016/j.bbrc.2004.09.213CrossRefPubMed Pani G, Fusco S, Colavitti R, Borrello S, Maggiano N, Cravero AA, Farre SM, Galeotti T, Koch OR: Abrogation of hepatocyte apoptosis and early appearance of liver dysplasia in ethanol-fed p53-deficient mice. Biochem Biophys Res Commun. 2004, 325: 97-100. 10.1016/j.bbrc.2004.09.213CrossRefPubMed
12.
go back to reference Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ, Prost S: Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer. 2007, 7: 215. 10.1186/1471-2407-7-215PubMedCentralCrossRefPubMed Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ, Prost S: Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer. 2007, 7: 215. 10.1186/1471-2407-7-215PubMedCentralCrossRefPubMed
13.
go back to reference Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y, Fausto N: Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology. 2008, 47: 2078-2088. 10.1002/hep.22194CrossRefPubMed Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y, Fausto N: Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology. 2008, 47: 2078-2088. 10.1002/hep.22194CrossRefPubMed
14.
go back to reference Hecht EM, Holland AE, Israel GM, Hahn WY, Kim DC, West AB, Babb JS, Taouli B, Lee VS, Krinsky GA: Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology. 2006, 239: 438-447. 10.1148/radiol.2392050551CrossRefPubMed Hecht EM, Holland AE, Israel GM, Hahn WY, Kim DC, West AB, Babb JS, Taouli B, Lee VS, Krinsky GA: Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology. 2006, 239: 438-447. 10.1148/radiol.2392050551CrossRefPubMed
15.
go back to reference Semelka RC, Martin DR, Balci C, Lance T: Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging. 2001, 13: 397-401. 10.1002/jmri.1057CrossRefPubMed Semelka RC, Martin DR, Balci C, Lance T: Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging. 2001, 13: 397-401. 10.1002/jmri.1057CrossRefPubMed
16.
go back to reference Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP, Prasad KR, Toogood GJ, Wyatt JI: Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology. 2005, 237: 170-180. 10.1148/radiol.2371041444CrossRefPubMed Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP, Prasad KR, Toogood GJ, Wyatt JI: Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology. 2005, 237: 170-180. 10.1148/radiol.2371041444CrossRefPubMed
17.
go back to reference Semelka RC, Helmberger TK: Contrast agents for MR imaging of the liver. Radiology. 2001, 218: 27-38.CrossRefPubMed Semelka RC, Helmberger TK: Contrast agents for MR imaging of the liver. Radiology. 2001, 218: 27-38.CrossRefPubMed
18.
go back to reference Thorgeirsson SS, Santoni-Rugiu E, Davis CD, Snyderwine EG: Hepatic tumor induction in c-myc mono-transgenic and TGF-alpha/c-myc double-transgenic mice. Arch Toxicol Suppl. 1997, 19: 359-366.CrossRefPubMed Thorgeirsson SS, Santoni-Rugiu E, Davis CD, Snyderwine EG: Hepatic tumor induction in c-myc mono-transgenic and TGF-alpha/c-myc double-transgenic mice. Arch Toxicol Suppl. 1997, 19: 359-366.CrossRefPubMed
19.
go back to reference Heindryckx F, Colle I, Van Vlierberghe H: Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009, 90: 367-386. 10.1111/j.1365-2613.2009.00656.xPubMedCentralCrossRefPubMed Heindryckx F, Colle I, Van Vlierberghe H: Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009, 90: 367-386. 10.1111/j.1365-2613.2009.00656.xPubMedCentralCrossRefPubMed
20.
go back to reference Kojiro M: 'Nodule-in-nodule' appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology. 2004, 47: 179-183. 10.1159/000078470CrossRefPubMed Kojiro M: 'Nodule-in-nodule' appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology. 2004, 47: 179-183. 10.1159/000078470CrossRefPubMed
21.
go back to reference Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M: Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007, 11: 119-132. 10.1016/j.ccr.2006.12.016CrossRefPubMed Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M: Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007, 11: 119-132. 10.1016/j.ccr.2006.12.016CrossRefPubMed
22.
go back to reference Weiler-Normann C, Herkel J, Lohse AW: Mouse models of liver fibrosis. Z Gastroenterol. 2007, 45: 43-50. 10.1055/s-2006-927387CrossRefPubMed Weiler-Normann C, Herkel J, Lohse AW: Mouse models of liver fibrosis. Z Gastroenterol. 2007, 45: 43-50. 10.1055/s-2006-927387CrossRefPubMed
23.
go back to reference Mueller GC, Hussain HK, Carlos RC, Nghiem HV, Francis IR: Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. AJR Am J Roentgenol. 2003, 180: 673-680.CrossRefPubMed Mueller GC, Hussain HK, Carlos RC, Nghiem HV, Francis IR: Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. AJR Am J Roentgenol. 2003, 180: 673-680.CrossRefPubMed
24.
go back to reference Lauenstein TC, Salman K, Morreira R, Heffron T, Spivey JR, Martinez E, Sharma P, Martin DR: Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol. 2007, 189: 663-670. 10.2214/AJR.07.2171CrossRefPubMed Lauenstein TC, Salman K, Morreira R, Heffron T, Spivey JR, Martinez E, Sharma P, Martin DR: Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol. 2007, 189: 663-670. 10.2214/AJR.07.2171CrossRefPubMed
25.
go back to reference Lee JS, Thorgeirsson SS: Comparative and integrative functional genomics of HCC. Oncogene. 2006, 25: 3801-3809. 10.1038/sj.onc.1209561CrossRefPubMed Lee JS, Thorgeirsson SS: Comparative and integrative functional genomics of HCC. Oncogene. 2006, 25: 3801-3809. 10.1038/sj.onc.1209561CrossRefPubMed
26.
go back to reference Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010, 140: 197-208. 10.1016/j.cell.2009.12.052PubMedCentralCrossRefPubMed Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010, 140: 197-208. 10.1016/j.cell.2009.12.052PubMedCentralCrossRefPubMed
27.
go back to reference Sakurai T, Maeda S, Chang L, Karin M: Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA. 2006, 103: 10544-10551. 10.1073/pnas.0603499103PubMedCentralCrossRefPubMed Sakurai T, Maeda S, Chang L, Karin M: Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA. 2006, 103: 10544-10551. 10.1073/pnas.0603499103PubMedCentralCrossRefPubMed
28.
go back to reference Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S: Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology. 2002, 123: 608-618. 10.1053/gast.2002.34756CrossRefPubMed Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S: Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology. 2002, 123: 608-618. 10.1053/gast.2002.34756CrossRefPubMed
29.
go back to reference Cohen B, Ziv K, Plaks V, Israely T, Kalchenko V, Harmelin A, Benjamin LE, Neeman M: MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med. 2007, 13: 498-503. 10.1038/nm1497CrossRefPubMed Cohen B, Ziv K, Plaks V, Israely T, Kalchenko V, Harmelin A, Benjamin LE, Neeman M: MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med. 2007, 13: 498-503. 10.1038/nm1497CrossRefPubMed
30.
go back to reference Maeda S, Kamata H, Luo JL, Leffert H, Karin M: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005, 121: 977-990. 10.1016/j.cell.2005.04.014CrossRefPubMed Maeda S, Kamata H, Luo JL, Leffert H, Karin M: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005, 121: 977-990. 10.1016/j.cell.2005.04.014CrossRefPubMed
31.
go back to reference Sarma DS, Rao PM, Rajalakshmi S: Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv. 1986, 5: 781-798.PubMed Sarma DS, Rao PM, Rajalakshmi S: Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv. 1986, 5: 781-798.PubMed
Metadata
Title
Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma
Authors
Julia Freimuth
Nikolaus Gassler
Nives Moro
Rolf W. Günther
Christian Trautwein
Christian Liedtke
Gabriele A. Krombach
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-94

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine